Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
Value Health Reg Issues
; 19: 34-44, 2019 Sep.
Article
en En
| MEDLINE
| ID: mdl-30776766
ABSTRACT
BACKGROUND:
The 13-valent pneumococcal conjugate vaccine (PCV13) is used for universal infant vaccination in Turkey.OBJECTIVES:
To assess the cost effectiveness of replacing PCV13 with pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).METHODS:
A Markov cohort model with monthly cycles following 1 cohort of infants over a 10-year time horizon was used. Local input parameters were obtained from published sources and expert consultation whenever possible. The model was adapted to estimate the health benefits and economic impact of each vaccine on invasive pneumococcal disease, pneumonia, and acute otitis media (AOM). An annual discount rate of 3% was used for benefits and costs (2016 euros).RESULTS:
Under base-case assumptions, vaccinating 1 birth cohort of 1 325 783 infants with PHiD-CV instead of PCV13 was predicted to have the same impact on meningitis and pneumonia, a similar impact on bacteremia (+30 cases), but greater reductions in AOM-related general practitioner visits (-34 955) and hospitalizations (-624). Assuming equal vaccine prices, PHiD-CV was predicted to be dominant over PCV13 (176 additional quality-adjusted life-years while saving 635 330 [discounted]). One-way sensitivity analysis indicated that varying the vaccine price differential had the largest effect on the incremental cost-effectiveness ratio, and then AOM parameters. Probabilistic sensitivity analysis predicted PHiD-CV to be dominant over PCV13 in 92.4% of simulations.CONCLUSIONS:
Any difference in price between PHiD-CV and PCV13 is expected to be the key driver of vaccine choice for preventing childhood pneumococcal disease in Turkey. At price parity, PHiD-CV use is likely to be a dominant strategy over the use of PCV13.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Otitis Media
/
Infecciones Neumocócicas
/
Análisis Costo-Beneficio
/
Vacunas Conjugadas
/
Vacunas Neumococicas
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
Límite:
Child
/
Child, preschool
/
Humans
/
Infant
País como asunto:
Asia
Idioma:
En
Año:
2019
Tipo del documento:
Article